Tradestie Institutional Equity Comparison Engine

LCTX vs SLN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

LCTX Overall Edge

LCTX Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Lineage Cell Therapeutics, Inc. (LCTX) driven by superior Valuation, Growth & Margin while SLN counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, LCTX trades at 30.7x Forward P/E with -280.3% operating margin (-61.0% YoY revenue) versus SLN at N/M Forward P/E and -11905.9% operating margin (+197.2% YoY). In options structure, LCTX sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro) against SLN sits in UNCLASSIFIED (50th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner LCTX
LCTX 30.7x vs SLN N/M Fwd P/E
Growth & Margin Winner LCTX
Op Margin -280.3% vs -11905.9% ยท YoY -61.0% vs +197.2%
Momentum & Technical Winner SLN
1Y -54.9% vs +208.1% ยท 52W Pos 0% vs 100%
Options & Structure Winner SLN
BREAKDOWN (<1st %ile IV) vs UNCLASSIFIED (50th %ile IV)
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.77
-5.87% 1D
Market Cap $207.4M
1M Return -21.63%
1Y Return -54.86%
Forward P/E 30.7x
Unified AI Score
54.9 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 72.0 Mom 45.0
SLN NASDAQ
Silence Therapeutics Plc American Depository Share
Pharmaceutical Preparations
$19.81
+0.0% 1D
Market Cap $1.2B
1M Return +0.76%
1Y Return +208.09%
Forward P/E N/M
Unified AI Score
45.6 / 100 HOLD
Tech 29.0 Fund 36.0 Flow 50.0 Mom 30.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LCTX -54.86% SLN +208.09% Spread: +262.95 pp (SLN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
LCTX TTM Op. Margin: -280.3% SLN TTM Op. Margin: -11905.9%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LCTX vs SLN. Trailing 12-month operating profitability (LCTX -280.3% vs SLN -11905.9%) and valuation multiples (LCTX 30.7x vs SLN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LCTX (6) vs SLN (4)
Institutional Metric LCTX SLN Criterion Row Winner
Market Capitalization Scale $207.4M $1.2B Larger Scale SLN
Trailing P/E Ratio Valuation 30.7x N/M Lower Multiple LCTX
Forward P/E Ratio Valuation 30.7x N/M Lower Multiple LCTX
Revenue Growth (YoY) Growth -61.0% +197.2% Higher Growth SLN
Operating Margin (TTM) Profitability -280.3% -11905.9% Higher Margin LCTX
Net Profit Margin Profitability 16.2% 0.0% Higher Margin LCTX
Return on Equity (ROE) Capital Efficiency 4.3% -35.6% Higher ROE LCTX
52-Week Range Position Momentum 0% ($1โ€“$2) 100% ($4โ€“$20) Stronger Trend SLN
Beta / 30D Volatility Risk Regime 1.39ฮฒ ยท 79% Vol 1.77ฮฒ ยท 4% Vol Lower Realized Risk SLN
Unified Institutional Score Composite Signal 54.9 / 100 (HOLD) 45.6 / 100 (HOLD) Higher Composite LCTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LCTX vs SLN Buy Guide
LCTX BREAKDOWN
7d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live LCTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SLN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 50th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live SLN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LCTX nor SLN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.